Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection

Reuters07-18

<a href="https://laohu8.com/S/SHEZF">Shenzhen Hepalink</a> Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection

Shenzhen Hepalink Pharmaceutical Group Co. Ltd. has announced a significant advancement in its clinical research endeavors with the enrollment of the first subject and completion of the first dosing in the Phase 1 clinical trial of its innovative drug, H1710 injection. This trial, which received approval from the National Medical Products Administration in February 2025, is designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors. H1710 is a heparin derivative developed as a selective heparanase inhibitor, targeting overexpressed heparanase in malignant tumors to exhibit anti-tumor activity. This marks the first human trial of the novel compound, showcasing Shenzhen Hepalink's commitment to advancing cancer treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2552465683?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-18 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552465683","market":"us","top_or_hot":-1,"title":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SHEZF\">Shenzhen Hepalink</a> Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/002399\">Shenzhen Hepalink</a> Pharmaceutical Group Co. Ltd. has announced a significant advancement in its clinical research endeavors with the enrollment of the first subject and completion of the first dosing in the Phase 1 clinical trial of its innovative drug, H1710 injection. This trial, which received approval from the National Medical Products Administration in February 2025, is designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors. H1710 is a heparin derivative developed as a selective heparanase inhibitor, targeting overexpressed heparanase in malignant tumors to exhibit anti-tumor activity. This marks the first human trial of the novel compound, showcasing Shenzhen Hepalink's commitment to advancing cancer treatment options.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-18 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SHEZF\">Shenzhen Hepalink</a> Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/002399\">Shenzhen Hepalink</a> Pharmaceutical Group Co. Ltd. has announced a significant advancement in its clinical research endeavors with the enrollment of the first subject and completion of the first dosing in the Phase 1 clinical trial of its innovative drug, H1710 injection. This trial, which received approval from the National Medical Products Administration in February 2025, is designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors. H1710 is a heparin derivative developed as a selective heparanase inhibitor, targeting overexpressed heparanase in malignant tumors to exhibit anti-tumor activity. This marks the first human trial of the novel compound, showcasing Shenzhen Hepalink's commitment to advancing cancer treatment options.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDLc7YL1H:1","article_id":"2552465683","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552465683","pubTimestamp":1752829341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0188":"融资融券","BK0070":"员工持股","BK0239":"医药制造","002399":"海普瑞"},"translate_title":"深圳海普瑞药业集团股份有限公司宣布H1710注射液1期临床试验首例受试者入组并完成首次给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002399":0.9},"content_text":"Shenzhen Hepalink Pharmaceutical Group Co. Ltd. Announces Enrollment of First Subject and Completion of First Dosing in Phase 1 Clinical Trial for H1710 Injection\n    \n\nShenzhen Hepalink Pharmaceutical Group Co. Ltd. has announced a significant advancement in its clinical research endeavors with the enrollment of the first subject and completion of the first dosing in the Phase 1 clinical trial of its innovative drug, H1710 injection. This trial, which received approval from the National Medical Products Administration in February 2025, is designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors. H1710 is a heparin derivative developed as a selective heparanase inhibitor, targeting overexpressed heparanase in malignant tumors to exhibit anti-tumor activity. This marks the first human trial of the novel compound, showcasing Shenzhen Hepalink's commitment to advancing cancer treatment options.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552465683","isCrawlerRequest":true}